About ArmaGen
ArmaGen is a Healthcare company based in United States founded in 2004, and was acquired by JCR Pharmaceuticals in March 2020. Therapies for severe neurological disorders are developed via BBB-crossing technology. ArmaGen has raised $17 million across 22 funding rounds from investors including Takeda Pharmaceuticals, HHS and JCR Pharmaceuticals. The company has 12 employees. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is ARMAGEN, INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
ArmaGen was founded in 2004 in the United States as a biotechnology company focused on treatments for severe neurological disorders. A proprietary platform is utilized to fuse therapeutics with antibodies that target receptors for insulin, transferrin, or LRP1, facilitating brain delivery through receptor-mediated transcytosis across the blood-brain barrier. Eight compounds are currently in development, with lead candidates AGT-182 for Hunter syndrome and AGT-181 for Hurler syndrome.
- Headquarters United States
- Employees 12
- Stage Acquired
- SectorsHealthcare
- Website armagen.com
- Social LinkedIn X
- Acquired by JCR Pharmaceuticals (Mar 2020)
- Legal Name Armagen, Inc.
- Total Equity Funding$17M (USD)
in 22 rounds
- Latest Funding Round$1.19M (USD), Grant
Jul 2014
- InvestorsTakeda Pharmaceuticals
& 6 more
- Employee Count12
- Acquired byJCR Pharmaceuticals
(Mar 2020)
Funding Insights of ArmaGen
ArmaGen has successfully raised a total of $17M across 22 strategic funding rounds. The most recent funding activity was a Grant round of $1.19 million completed in July 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17M
- Total Rounds 22
- Last Round Grant — $1.19M
- First Round $1.16M
(Jul 2007)
- Investors Count 6
Latest 10 of 22 funding rounds of ArmaGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2014 | $1.19M | Grant | – | – | |
| Mar 2013 | $981,134 | Grant | – | – | |
| Nov 2012 | $17M | Series A | – | Boehringer Ingelheim Venture Fund | |
| Aug 2012 | $1.16M | Grant | – | – | |
| Apr 2012 | $148,530 | Grant | – | – | |
| Dec 2011 | $1.05M | Grant | – | – | |
| Apr 2011 | $149,800 | Grant | – | – | |
| Mar 2011 | $842,946 | Grant | – | – | |
| Feb 2011 | $111,214 | Grant | – | – | |
| Jan 2011 | $111,214 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in ArmaGen
ArmaGen has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, HHS and JCR Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
Corporate-backed venture capital firm focused on healthcare, IT, and multiple sectors | mitsui-global.com | Menlo Park, United States | ||
| takedaventures.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Rare disease treatments are developed by a specialty biopharmaceutical firm. | 1986 | shire.com | Dublin, Ireland | |
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States | ||
Biosimilars and cell therapies are manufactured and commercialized. | 1975 | jcrpharm.co.jp | Hyogo, Japan |
Investor details for ArmaGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ArmaGen
3 people are tracked at ArmaGen (2 in leadership, 1 in board & advisors); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Doug Hunt | Vice President Regulatory Affairs and Quality Assurance | Leadership |
William M. Pardridge | Founder & Chief Scientific Officer | Leadership |
Jayson Punwani | Director | Board & advisors |
Complete people profiles for ArmaGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ArmaGen
4 dated milestones of ArmaGen across 16 years, from founding to its latest funding, stage changes and deals.
- Founded ArmaGen is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Grant, of $1.2M.
- Exit Acquired by JCR Pharmaceuticals.
Competitors of ArmaGen
ArmaGen has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of ArmaGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ArmaGen
Websites that share an audience with ArmaGen (armagen.com).
Websites whose visitors overlap most with ArmaGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cen.acs.org | cen.acs.org | 100% | – | ||
magnified-world.tumblr.com | magnified-world.tumblr.com | 92% | – | ||
| wicab.com | 89% | 2.3K | #7,770,193 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as ArmaGen (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Armagen
Complete news archive for ArmaGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ArmaGen
ArmaGen was founded in 2004 and raised its 1st funding round 3 years after it was founded.
ArmaGen is headquartered in United States.
ArmaGen is a funded company, having raised a total of $17M across 22 funding rounds to date. The company's 1st funding round was a Grant of $111.21K, raised on Jul 2007.
ArmaGen has 12 employees.
ArmaGen was founded in 2004 in the United States as a biotechnology company focused on treatments for severe neurological disorders. A proprietary platform is utilized to fuse therapeutics with antibodies that target receptors for insulin, transferrin, or LRP1, facilitating brain delivery through receptor-mediated transcytosis across the blood-brain barrier. Eight compounds are currently in development, with lead candidates AGT-182 for Hunter syndrome and AGT-181 for Hurler syndrome.
ArmaGen has 7 investors. Key investors include Takeda Pharmaceuticals, HHS, JCR Pharmaceuticals, Boehringer Ingelheim Venture Fund, and Mitsui Global Investment.
ArmaGen operates through Armagen, Inc..
Yes. ArmaGen was acquired by JCR Pharmaceuticals in March 2020.